Accenture: Acquisition Of Early-Stage Assets, Bio-Platforms Key To Accelerated Growth
Executive Summary
Acquisitions of early-stage assets, biotech platforms and capabilities like AI are the way to faster growth for pharma companies, as Accenture’s Petra Jantzer told In Vivo. However, changing the focus of M&A away from conventional late-stage assets requires significant shifts in corporate and R&D culture.
You may also be interested in...
Takeda Buys Out Partner GammaDelta In Cell Therapy Push
Japanese major buys out existing cancer cell therapy research partner, exercising an exclusive option dating back to a 2017 collaboration and expanding its immuno-oncology ambitions and pipeline.
The Inside Story On How Bayer Swooped On NASDAQ-Bound Vividion
It has taken just seven weeks from a cold call to completion and the German major has got its hands on a prized asset in Vividion which was on the verge of listing on the NASDAQ. The companies told Scrip how the deal was done.
Sanofi Goes All The Way In mRNA With Translate Bio Buy
Taking full control of partner Translate Bio means that Sanofi is the only big vaccine company with a wholly-owned mRNA platform in-house but observers say it is too early to declare that the Paris-headquartered group has bagged itself a bargain.